Do you want to read an article? Please log in or register.
Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
Psoriasis
Related content
Psoriasis
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
J Am Acad Dermatol.
Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A
doi: 10.1016/j.jaad.2017.08.051.
Psoriasis
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years
J Eur Acad Dermatol Venereol.
Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G
doi: 10.1111/jdv.15637.
COMMENTED
PsoriasisRheumatoid Arthritis
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
doi: 10.1016/S2468-1253(19)30362-0.
Psoriasis
Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review
JAMA Dermatol.
van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK
doi: 10.1001/jamadermatol.
Rheumatoid Arthritis
Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study
Clin Exp Rheumatol.
Burmester G, Nüsslein H,
von Hinüber U, Detert J, Richter C, Kumke T, Leunikava I, Lendl U, Fricke D, Müller-Ladner U
Psoriasis
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials
Br J Dermatol.
Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R
doi: 10.1111/bjd.17318.
Psoriasis
Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study
J Eur Acad Dermatol Venereol.
Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M
doi: 10.1111/jdv.15962.
Rheumatoid Arthritis
Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
Lancet.
Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S
doi: 10.1016/
Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology
Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever
Rheumatology (Oxford).
Ugurlu S, Ergezen B, Egeli BH, Selvi O, Ozdogan H
doi: 10.1093/rheumatology/keaa211.